This review evaluated the effectiveness of rifampin as an adjunctive therapy to treat Staphylococcus aureus infections. The evidence suggests that rifampin may be promising in certain clinical scenarios, but this conclusion may not be reliable given the limitations in the review data, particularly with regard to methodological quality.
Study selection
Studies comparing quantitative bacterial measurements, cure rates or staphylococcal-related mortality rates of one or more antibiotics alone and in combination with rifampin, and studies of the efficacy of one or more antibiotics alone and in combination with rifampin, were eligible for inclusion. Studies of the efficacy of rifampin alone compared with other antibiotics, rifampin as prophylaxis to prevent infection in uninfected hosts, and the use of rifampin impregnated devices or catheters, were excluded.
Studies of patients with a wide range of conditions were included in the review (cellulitis, wounds, pneumonia, urinary tract infection, endocarditis, bacteraemia, osteomyelitis, septic arthritis, catheter related empyema, orthopaedic hardware infections and other conditions). The authors reported that the included patients varied in terms of comorbidities, sites of infection and acuity of infection. The included studies investigated a variety of doses and dosing regimens of the antibiotics vancomycin, pefloxacin, ciprofloxacin, oxacillin, fleroxacin and nafcillin, given orally and intravenously. Rifampin doses varied from 300 to 1,200 mg/day and was given orally and intravenously. Where reported, the included studies reported results for the methicillin-susceptible and methicillin-resistant S. aureus strains. A variety of outcomes, including cure, clinical improvement and persistence of bacteraemia, were reported. The included studies were randomised prospective and randomised prospective placebo-controlled trials, randomised prospective cohort analysis and a retrospective study. The follow-up period varied from several days to over 3 years.
Two reviewers independently selected the studies and a third reviewer resolved any disagreements.
Assessment of study quality
Methodological quality was assessed using the Jadad scale, a 5-point scale evaluating randomisation, blinding and allocation concealment.
Two independent two reviewers performed the assessment and a third reviewer resolved any disagreements.
Data extraction
Clinical cure, failure to respond, improvement, bacteriologic failure, duration of bacteraemia, duration of fever, cure negative, explanted hardware, cure without hardware removal, possible cure, probable cure, remission, definite relapse, persistent infection and overall favourable response were extracted. Statistical analysis was performed for studies that had reported results but no analysis. Dichotomous outcomes were analysed using a χ 2 or Fisher exact test, and for studies comparing means the Wilcoxon rank sum test was used (if standard deviations and group sample sizes were
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Two independent reviewers extracted the data into a standardised form and checked for accuracy; any discrepancies in the data were resolved through discussion.
Methods of synthesis
Differences between the studies precluded a quantitative analysis. The studies were grouped according to the antibiotic used and summarised in a narrative with accompanying data tables.
Results of the review
Seven studies were included in the review: two randomised, prospective placebo-controlled trials, three randomised prospective trials, one randomised prospective cohort analysis and one retrospective study. The number of participants in each study was not reported, but the authors stated that the study populations were between 15 and 65 patients.
The mean Jadad score of the included studies was two, the median one (range: 0 to 5).
Two trials investigated oxacillin or vancomycin in patients with a variety of infection types. These showed a statistically significant improvement in clinical cure rates in the dual therapy group (p=0.02 and p<0.05). The authors also reported that a trial that treated hardware infections with fluoroquinolones achieved clinical cure more often with dual therapy (p=0.002), and cure rates were statistically significantly improved in patients treated with dual therapy compared with the monotherapy group in an as-treated analysis (p=0.04).
There were no statistically significant differences between dual and monotherapy groups in the studies of nafcillin, vancomycin, pefloxacin and ciprofloxacin (it is unclear which specific outcomes the p-values corresponded to in the tables).
